Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Leases (2016 - 2025)

Arrowhead Pharmaceuticals' Leases history spans 16 years, with the latest figure at $43.4 million for Q4 2025.

  • For Q4 2025, Leases fell 3.36% year-over-year to $43.4 million; the TTM value through Dec 2025 reached $43.4 million, down 3.36%, while the annual FY2025 figure was $43.9 million, 3.01% down from the prior year.
  • Leases reached $43.4 million in Q4 2025 per ARWR's latest filing, down from $43.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $96.3 million in Q2 2023 to a low of $33.1 million in Q1 2021.
  • Average Leases over 5 years is $47.7 million, with a median of $44.2 million recorded in 2024.
  • Peak YoY movement for Leases: surged 72.54% in 2021, then plummeted 53.98% in 2024.
  • A 5-year view of Leases shows it stood at $42.0 million in 2021, then increased by 0.1% to $42.0 million in 2022, then rose by 6.88% to $44.9 million in 2023, then dropped by 0.08% to $44.9 million in 2024, then fell by 3.36% to $43.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Leases are $43.4 million (Q4 2025), $43.9 million (Q3 2025), and $44.0 million (Q2 2025).